There are also genetic events upstream of RB1 that may be present in breast tumours, which can negatively impact RB1 function by promoting its phosphorylation, that include p16INK4a loss [7] and cyclin D1 amplification/overexpression [8]. Here, CDKN2A is linked to breast neoplasm.